Life Science Leader Magazine

FEB 2014

The vision of Life Science Leader is to be an essential business tool for life science executives. Our content is designed to not only inform readers of best practices, but motivate them to implement those best practices in their own businesses.

Issue link: https://lifescienceleadermag.epubxp.com/i/250657

Contents of this Issue

Navigation

Page 30 of 53

Exclusive Life Science Feature no shortage of Alzheimer's patients." Garnett ronment?" Garnett thinks the industry needs believes if patient engagement works well for to challenge itself to improve the patient healthcare providers like hospitals, why not and investigator experience. One solution take the same approach when trying to recruit involved the collaboration between Lilly, J&J;, for clinical trials. "We are looking at running a and Merck to share trial investigator good Muscular Dystrophy trial. As a result, we are in clinical practice (GCP) training information. very close contact with MD support groups," Prior to this, if investigators worked for one he shares. "We know that when we are ready of these companies, they had to do three to start, we will have every patient ready to separate, and essentially the same, training be screened and entered." Getting better at sessions. The collaborative effort to share the recruiting is a critical component to successful GCP info was well received by the industry. It clinical trial execution. So too is getting folks eliminated redundant training, saving money to want to participate more than once. for everyone, and the investigators' most "The biggest determining factor of how long it is going to take to run One of the realities in the clinical trial space a Phase 3 study is the amount of time it takes to recruit patients," valuable resource — time. TransCelerate is the majority of patients and investigators says Timothy Garnett, chief medical officer, Eli Lilly BioPharma, which now numbers nearly 20 who participate in a study do so only once. member companies, built upon this in devel"What factors make this an experience participants often don't oping its site qualification and training resources. want to repeat?" asks Garnett. "How can we become more patient There are a number of ways to improve the clinical trial experiand investigator friendly in an ever increasingly competitive envience for patients. For example, participating in a placebo-con- DATATRAK ONE® Delivering the Complete unified eClinical Experience EŽKŶĞůƐĞKīĞƌƐĂdƌƵůLJ uŶŝĮĞĚ^ŽůƵƟŽŶ EŽKŶĞ Phase I Phase II ͻ Phase III ͻ Phase IV Quicker Training &ĂƐƚĞƌsĂůŝĚĂƟŽŶͻ Easier Change Orders ĞƩĞƌĂƚĂͻWĞƌŝŽĚ datatrak.com +1.440.443.0082 ŵĂƌŬĞƟŶŐΛĚĂƚĂƚƌĂŬ͘ĐŽŵ February 2014 LifeScienceLeader.com 29

Articles in this issue

Links on this page

Archives of this issue

view archives of Life Science Leader Magazine - FEB 2014